Abstract
By systematic analysis of a human testis library, we have isolated the hH-Rev107-3 cDNA, identical to hH-Rev107-1 cDNA, which was previously described as a class II tumor suppressor gene. In this study, two transcripts (1 and 0.8 kb) were detected by Northern blot in all human tissues, excepted in thymus. The strongest expression was found in testis, skeletal muscle and heart. These two mRNA are probably transcribed from only one gene that we mapped to the q12-q13 region of the chromosome 11. In human testis, hH-Rev107 gene expression was localized, by in situ hybridization, within the round spermatids. To investigate a possible role for hH-Rev107 protein in testicular malignant growth, we examined the expression of this gene in germ cell tumors. A strong hH-Rev107 gene expression was observed in normal testis as well as in samples with preinvasive carcinoma in situ but was completely absent in overt tumors, both seminomas and non-seminomas. By in situ hybridization, CIS was found hH-Rev107 positive and tumor negative. A semi-quantitative assessment of hH-Rev107 mRNA level in testicular germ cell tumors, by RT–PCR, exhibited a ninefold decrease in the gene expression. No gross structural aberrations of hH-Rev107 gene were detected in these human primary tumors. The results suggest that down-regulation of hH-Rev107 may be associated with invasive progression of testicular germ cell tumors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bartkova J, Thullberg M, Rajpert-De Meyts E, Skakkebaek NE, Bartek J . 2000 Int. J. Cancer 85: 370–375
Bos JL . 1989 Cancer Res. 49: 4682–4689
Braun RE . 1998 Semin. Cell. Dev. Biol. 9: 483–489
Bulle F, Lespinasse J, Pawlak A, Vadot E, Sastre J, Noel B, Guellaen G . 1996 Ann. Genet. 39: 139–143
Chomczynski P, Sacchi N . 1987 Anal. Biochem. 162: 156–159
DiSepio D, Ghosn C, Eckert RL, Deucher A, Robinson N, Duvic M, Chandraratna RA, Nagpal S . 1998 Proc. Natl. Acad. Sci. USA 95: 14811–14815
Duvic M, Helekar B, Schulz C, Cho M, DiSepio D, Hager C, DiMao D, Hazarika P, Jackson B, Breuer-McHam J, Young J, Clayman G, Lippman SM, Chandraratna RA, Robinson NA, Deucher A, Eckert RL, Nagpal S . 2000 Clin. Cancer Res. 6: 3249–3259
Erickson RP . 1990 Trends Genet. 6: 264–269
Hajnal A, Klemenz R, Schafer R . 1994 Oncogene 9: 479–490
Hecht NB . 1998 Bioessays 20: 555–561
Huang SL, Shyu RY, Yeh MY, Jiang SY . 2000 Mol. Cell. Endocrinol. 159: 15–24
Husmann K, Sers C, Fietze E, Mincheva A, Lichter P, Schafer R . 1998 Oncogene 17: 1305–1312
Lee SW, Tomasetto C, Sager R . 1991 Proc. Natl. Acad. Sci. USA 88: 2825–2829
Levy I, Wu YQ, Roeckel N, Bulle F, Pawlak A, Siegrist S, Mattei MG, Guellaen G . 1996 FEBS Lett. 382: 276–280
Mattei MG, Philip N, Passage E, Moisan JP, Mandel JL, Mattei JF . 1985 Hum. Genet. 69: 268–271
Moul JW, Theune SM, Chang EH . 1992 Genes Chromosomes Cancer 5: 109–118
Mulder MP, Keijzer W, Verkerk A, Boot AJ, Prins ME, Splinter TA, Bos JL . 1989 Oncogene 4: 1345–1351
Pawlak A, Toussaint C, Levy I, Bulle F, Poyard M, Barouki R, Guellaen G . 1995 Genomics 26: 151–158
Peckham M . 1988 Acta. Oncol. 27: 439–453
Rajpert-De Meyts E, Jorgensen N, Brondum-Nielsen K, Muller J, Skakkebaek NE . 1998 Apmis 106: 198–204 discussion 204–206
Richie JP . 1993 CA Cancer J. Clin. 43: 151–175
Saccone S, De Sario A, Della Valle G, Bernardi G . 1992 Proc. Natl. Acad. Sci. USA 89: 4913–4917
Schmidt B, Ackermann R, Strohmeyer T . 1995 J. Mol. Med. 73: 355–367
Schmidt EE, Schibler U . 1995 Development 121: 2373–2383
Sers C, Emmenegger U, Husmann K, Bucher K, Andres AC, Schafer R . 1997 J. Cell. Biol. 136: 935–944
Shuin T, Misaki H, Kubota Y, Yao M, Hosaka M . 1994 Cancer 73: 1721–1727
Skakkebaek NE . 1972 Lancet 2: 516–517
Skakkebaek NE, Berthelsen JG, Giwercman A, Muller J . 1987 Int. J. Androl. 10: 19–28
Acknowledgements
We thank Y Laperche for helpful discussion and J Hinrichsen H Kistrup and C. Deschamps for excellent technical assistances. INSERM and the Danish Cancer Society funded this work.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Siegrist, S., Féral, C., Chami, M. et al. hH-Rev107, a class II tumor suppressor gene, is expressed by post-meiotic testicular germ cells and CIS cells but not by human testicular germ cell tumors. Oncogene 20, 5155–5163 (2001). https://doi.org/10.1038/sj.onc.1204658
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204658
Keywords
This article is cited by
-
H-rev107 regulates prostaglandin D2 synthase-mediated suppression of cellular invasion in testicular cancer cells
Journal of Biomedical Science (2013)
-
Cloning and functional characterization of the HRASLS2 gene
Amino Acids (2008)
-
RARRES3 expression positively correlated to tumour differentiation in tissues of colorectal adenocarcinoma
British Journal of Cancer (2003)